WCN26-9046 PEGCETACOPLAN FOR 52 WEEKS MAINTAINS PROTEINURIA REDUCTION AND EGFR STABILIZATION FOR PEDIATRIC PATIENTS: PHASE 3 VALIANT SUBGROUP ANALYSIS